426 related articles for article (PubMed ID: 35912647)
21. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Yang S; Kang J; Park KW; Hur SH; Lee NH; Hwang D; Yang HM; Ahn HS; Cha KS; Jo SH; Ryu JK; Suh IW; Choi HH; Woo SI; Han JK; Shin ES; Koo BK; Kim HS
J Am Coll Cardiol; 2023 Oct; 82(16):1565-1578. PubMed ID: 37821166
[TBL] [Abstract][Full Text] [Related]
22. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.
Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
Cardiovasc Interv Ther; 2021 Jan; 36(1):91-103. PubMed ID: 32086787
[TBL] [Abstract][Full Text] [Related]
23. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Palmerini T; Della Riva D; Benedetto U; Bacchi Reggiani L; Feres F; Abizaid A; Gilard M; Morice MC; Valgimigli M; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Colombo A; Chieffo A; Sangiorgi D; Biondi-Zoccai G; Généreux P; Angelini GD; Pufulete M; White J; Bhatt DL; Stone GW
Eur Heart J; 2017 Apr; 38(14):1034-1043. PubMed ID: 28110296
[TBL] [Abstract][Full Text] [Related]
24. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
[TBL] [Abstract][Full Text] [Related]
25. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
26. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials.
Shoji S; Kuno T; Ueyama H; Takagi H; Briasoulis A; Kim HS; Koo BK; Kang J; Watanabe H; Kimura T; Kohsaka S
J Cardiol; 2024 May; 83(5):338-347. PubMed ID: 37562542
[TBL] [Abstract][Full Text] [Related]
27. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
[TBL] [Abstract][Full Text] [Related]
29. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
[TBL] [Abstract][Full Text] [Related]
30. Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Shin ES; Jun EJ; Kim B; Won KB; Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Han JK; Kim HS;
J Am Heart Assoc; 2023 Apr; 12(8):e026770. PubMed ID: 37042284
[TBL] [Abstract][Full Text] [Related]
31. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
[TBL] [Abstract][Full Text] [Related]
32. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
33. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
Choo EH; Choi IJ; Lim S; Moon D; Kim CJ; Park MW; Kim MC; Hwang BH; Lee KY; Seok Choi Y; Kim HY; Yoo KD; Jeon DS; Ahn Y; Chang K;
Circ Cardiovasc Interv; 2022 Dec; 15(12):e012157. PubMed ID: 36382599
[TBL] [Abstract][Full Text] [Related]
34. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
35. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
36. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
[TBL] [Abstract][Full Text] [Related]
37. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
[TBL] [Abstract][Full Text] [Related]
38. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
[TBL] [Abstract][Full Text] [Related]
39. Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Lee YJ; Cho JY; Yun KH; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
EuroIntervention; 2022 Aug; 18(6):471-481. PubMed ID: 35470799
[TBL] [Abstract][Full Text] [Related]
40. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation.
Natsuaki M; Morimoto T; Yamamoto E; Watanabe H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Hanaoka KI; Tanabe K; Kozuma K; Kimura T;
PLoS One; 2020; 15(3):e0227612. PubMed ID: 32210433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
